6:02 PM
 | 
Dec 13, 2012
 |  BC Extra  |  Company News

Catalent, UMN in cell line deal for biosimilars

Catalent Pharma Solutions Inc. (Somerset, N.J.) granted UMN Pharma Inc. (Akita, Japan) rights to use Catalent's GPEx gene product expression technology to...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >